Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Ingo Schwaner, Holger F. Hebart, Christoph Losem, Thomas Wolff, Caroline Lehmann, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi

Blood (2023) 142 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2023-174387

Published: 2023

Journal Articles

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Ingo Schwaner, Holger Hebart, Christoph Losem, Thomas Wolff, Kirsten Famulla, Johannes Huelsenbeck, Burkhard Schmidt, Petra Pichler, Davide Rossi, Thomas Noesslinger

Blood (2022) 140 (Supplement 1): 12412–12413.

https://doi.org/10.1182/blood-2022-162273

Published: 2022

Journal Articles

Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naïve and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study

Davide Rossi, Holger Hebart, Christoph Losem, Thomas Wolff, Xenia Schmidt, Kirsten Famulla, Burkhard Schmidt, Thomas Noesslinger, Ingo Schwaner

Blood (2021) 138 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2021-145555

Published: 2021

Journal Articles

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Fabian Zohren, Ingmar Bruns, Sabrina Pechtel, Thomas Schroeder, Roland Fenk, Akos Czibere, Georg Maschmeyer, Dorothea Kofahl-Krause, Norbert Niederle, Gerhard Heil, Christoph Losem, Manfred Welslau, Wolfram Brugger, Ulrich Germing, Ralf Kronenwett, Juergen Barth, Mathias J. Rummel, Rainer Haas, Guido Kobbe

Blood (2015) 126 (12): 1407–1414.

https://doi.org/10.1182/blood-2015-03-630012

Published: 2015

Includes: Supplemental data

Journal Articles

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Blood (2014) 124 (21): 4407.

https://doi.org/10.1182/blood.V124.21.4407.4407

Published: 2014

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD, Wolfram Brugger, MD

Blood (2014) 124 (21): 145.

https://doi.org/10.1182/blood.V124.21.145.145

Published: 2014

Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth

Blood (2010) 116 (21): 856.

https://doi.org/10.1182/blood.V116.21.856.856

Published: 2010

Journal Articles

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Fabian Zohren, Ingmar Bruns, MD, PhD, Juergen Barth, Sabrina Pechtel, Roland Fenk, Thomas Schroeder, Akos G. Czibere, MD, Georg Maschmeyer, Dorothea Kofahl-Krause, Gerhard Heil, Norbert Niederle, Christoph Losem, Manfred Welslau, Ulrich Germing, Ralf Kronenwett, Rainer Haas, Mathias J Rummel, MD, PhD, Guido Kobbe, MD

Blood (2009) 114 (22): 441.

https://doi.org/10.1182/blood.V114.22.441.441

Published: 2009

Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger

Blood (2009) 114 (22): 405.

https://doi.org/10.1182/blood.V114.22.405.405

Published: 2009

Journal Articles

Deferasirox (Exjade ® ) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange.

Norbert Gattermann, Oliver Leismann, Rudolf Schlag, Klaus Blumenstengel, Mariele Goebeler, Matthias Groschek, Christoph Losem, Maria Procaccianti, Sieglinde Stern, Alexia Nass, Ulrich Germing

Blood (2009) 114 (22): 3805.

https://doi.org/10.1182/blood.V114.22.3805.3805

Published: 2009

Journal Articles

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, MD, Georg Hess, MD, Hubert Koeppler, MD, Jochen Heymanns, MD, Joerg Thomalla, MD, Ali Aldaoud, MD, Christoph Losem, MD, Stefan Schmitz, MD, Ursula Haak, MD, Christoph Huber, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD

Blood (2006) 108 (11): 2480.

https://doi.org/10.1182/blood.V108.11.2480.2480

Published: 2006

NARROW

Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland

Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve

Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naïve and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.

Deferasirox (Exjade ® ) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange.

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only